Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update

Dominari Holdings Inc. (NASDAQ:DOMH) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 15,600 shares, an increase of 578.3% from the March 31st total of 2,300 shares. Based on an average trading volume of 12,300 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.3% of the company’s shares are short sold.

Dominari Price Performance

Shares of NASDAQ DOMH traded down $0.06 during midday trading on Thursday, reaching $2.70. 8,450 shares of the stock were exchanged, compared to its average volume of 12,061. The business has a 50-day simple moving average of $2.39 and a two-hundred day simple moving average of $2.26. The company has a market capitalization of $16.01 million, a price-to-earnings ratio of -0.61 and a beta of 0.91. Dominari has a 12 month low of $1.76 and a 12 month high of $3.67.

Dominari (NASDAQ:DOMH) last announced its quarterly earnings results on Monday, April 1st. The company reported ($1.28) earnings per share for the quarter. The firm had revenue of $1.01 million for the quarter.

Insider Buying and Selling at Dominari

In other Dominari news, President Kyle Michael Wool acquired 8,500 shares of Dominari stock in a transaction on Monday, April 8th. The shares were purchased at an average cost of $2.99 per share, with a total value of $25,415.00. Following the completion of the purchase, the president now owns 22,750 shares in the company, valued at $68,022.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have acquired 31,444 shares of company stock valued at $90,278. 9.74% of the stock is currently owned by insiders.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.